Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-08 pm EDT			5-day change	1st Jan Change
295.05 ^USD	-0.29%		-0.36%	-25.80%

May. 01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
Apr. 30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Transcript : Alnylam Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01

Published on 09/03/2025 at 03:20 pm EDT - Modified on 09/03/2025 at 04:51 pm EDT

S&P Capital IQ

Presenter Speech
David Lebowitz (Analysts)

Thank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston. Next on the docket, we have Alnylam. If you could, I guess, introduce us and

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Alnylam Pharmaceuticals, Inc.

May. 01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
Apr. 30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	Alnylam Pharmaceuticals, Inc., Q1 2026 Earnings Call, Apr 30, 2026
Apr. 30	Alnylam Pharmaceuticals Q1 Adjusted Net Income, Revenue Rise; Reiterates 2026 Product Revenue Guidance -- Shares Up Pre-Bell	MT
Apr. 30	(ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B	MT
Apr. 30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q1 Revenue $1.17B, vs. FactSet Est of $1.12B	MT
Apr. 30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $1.99 per Share	MT
Apr. 06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
Mar. 30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI
Mar. 24	Alnylam Pharmaceuticals, Inc. - Special Call
Mar. 24	Alnylam Pharmaceuticals, Inc. Advances ATTR-CM Care with Strategic Collaboration and AI-Enabled Pathways	CI
Mar. 24	Alnylam Pharmaceuticals, Viz.ai Collaborate on AI-Enabled Detection of Transthyretin Amyloidosis	MT
Mar. 05	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI
Mar. 05	Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments	RE
Mar. 05	Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam	MT